Skip to main content
SpringerLink
Log in
Book cover

Breast Disease pp 463–472Cite as

Triple-Negative Breast Cancer

  • Chapter
  • First Online:

  • 2652 Accesses

Abstract

Triple-negative breast cancer (TNBC) was a term introduced in the literature in 2005 and has become a focus of research for both clinical investigators and basic scientists.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   189.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.

    Article  PubMed  Google Scholar 

  2. International Agency for Research on Cancer. 2008 http://www-dep.iarc.fr/. [cited 2012; International data on cancer statistics].

  3. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48.

    Article  CAS  PubMed  Google Scholar 

  4. Kaplan HG, Malmgren J, Atwood MK, Impact of triple negative phenotype on breast cancer prognosis. San Antonio Breast Cancer Symposium. 2006 (Dec 2006). p. poster session VI.

    Google Scholar 

  5. Kaplan HG, Malmgren JA, Atwood M. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J. 2009;15(5):454–60.

    Article  PubMed  Google Scholar 

  6. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9 Suppl 2:S73–81.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26(15):2568–81.

    Article  PubMed  Google Scholar 

  8. Carey LA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.

    Article  CAS  PubMed  Google Scholar 

  9. Lakhani SR, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9):2310–8.

    Article  CAS  PubMed  Google Scholar 

  10. Sorlie T, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418–23.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Rocque G, et al. Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. Breast Cancer Res Treat. 2012;131(2):713–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.

    Article  CAS  PubMed  Google Scholar 

  13. Sorlie T, et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther. 2006;5(11):2914–8.

    Article  CAS  PubMed  Google Scholar 

  14. Sorlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Sorlie T, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006;7:127.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Rakha EA, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25–32.

    Article  CAS  PubMed  Google Scholar 

  17. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360(8):790–800.

    Article  CAS  PubMed  Google Scholar 

  18. Korsching E, et al. Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol. 2008;61(5):553–60.

    Article  CAS  PubMed  Google Scholar 

  19. Mallon E, et al. The basic pathology of human breast cancer. J Mammary Gland Biol Neoplasia. 2000;5(2):139–63.

    Article  CAS  PubMed  Google Scholar 

  20. De Giorgi U, et al. High-dose chemotherapy for triple negative breast cancer. Ann Oncol. 2007;18(1):202–3.

    Article  PubMed  Google Scholar 

  21. Carey LA, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329–34.

    Article  CAS  PubMed  Google Scholar 

  22. Liedtke C, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–81.

    Article  PubMed  Google Scholar 

  23. Heitz FP, Harter, Traut A, Lueck HJ, Beutel B, du Bois A. Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors. Chicago: ASCO; 2008.

    Google Scholar 

  24. Miller K, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–76.

    Article  CAS  PubMed  Google Scholar 

  25. Freedman GM, et al. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer. 2009;115(5):946–51.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Haffty BG, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24(36):5652–7.

    Article  PubMed  Google Scholar 

  27. Voduc KD, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684–91.

    Article  PubMed  Google Scholar 

  28. Abdulkarim BS, et al. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol. 2011;29(21):2852–8.

    Article  PubMed  Google Scholar 

  29. Kandel MJ, ZS, Masciari S, Collins L, Schnitt S, Harris L, Miron A, Richardson A, Garber JE. Prevalence of BRCA1 mutations in triple negative breast cancer (BC) in 2006 ASCO annual meeting A.S.o.C. Oncology, Editor 2006.

    Google Scholar 

  30. Somer R, DF-C, Patel A, Schwarting R, Grana G, Rodler E. Screening for BRCA1 mutations in patients with triple negative breast cancer and basal phenotype. In: Research C editor. Thirty-second annual CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio; 2009. p. Supplement 3.

    Google Scholar 

  31. Heemskerk-Gerritsen BA, et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol. 2007;14(12):3335–44.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Kell MR, Burke JP. Management of breast cancer in women with BRCA gene mutation. BMJ. 2007;334(7591):437–8.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast. 2006;16:104.

    Article  PubMed  Google Scholar 

  34. Rottenberg S, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008;105(44):17079–84.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Farmer H, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.

    Article  CAS  PubMed  Google Scholar 

  36. O’Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, Rocha C, Ossovskaya V, Sherman B, Bradley C. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. Orlando: ASCO; 2009.

    Google Scholar 

  37. Carey LA, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30(21):2615–23.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Craig DW, et al. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther. 2013;12(1):104–16.

    Article  CAS  PubMed  Google Scholar 

  39. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.

    Google Scholar 

  40. Kwon JS, et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010;28(27):4214–20.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Breast Oncology and Experimental Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA

    Roohi Ismail-Khan MD, MS & Susan Minton DO

  2. Department of Women’s Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA

    Nazanin Khakpour MD, FACS

Authors
  1. Roohi Ismail-Khan MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan Minton DO
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nazanin Khakpour MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roohi Ismail-Khan MD, MS .

Editor information

Editors and Affiliations

  1. Advocate Center for Breast Health, Advocate Cancer Institute, Oak Lawn, Illinois, USA

    Adam I. Riker

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ismail-Khan, R., Minton, S., Khakpour, N. (2015). Triple-Negative Breast Cancer. In: Riker, A. (eds) Breast Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1145-5_29

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1145-5_29

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1144-8

  • Online ISBN: 978-1-4939-1145-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation